{"filings":[{"id":95369,"accession_number":"0001213900-26-044672","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"HeartBeam closes $10M public offering of 12.5M shares at $0.80 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 12.5M shares at $0.80, gross proceeds $10M; underwriter option for 1.875M additional shares.","Offering led by ClearCardio (first commercial customer), management, board, and existing investors.","Net proceeds to fund commercialization of FDA-cleared synthesized ECG system, extended-wear patch, heart attack detection, AI, and working capital.","Titan Partners Group acted as sole bookrunner; offering closed April 16, 2026.","Common stock (BEAT) and warrants (BEATW) trade on NASDAQ."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124842,"accession_number":"0001213900-25-113353","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"HeartBeam receives FDA NSE letter for 12-Lead ECG Synthesis 510(k), will seek resolution","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA issued a Not Substantially Equivalent (NSE) letter for HeartBeam's 12-Lead ECG Synthesis Software 510(k) on Nov 20, 2025.","Company stands behind its clinical data and will work with FDA to resolve the NSE determination.","HeartBeam is evaluating launching its 3D ECG system, which received FDA clearance in December 2024.","No financial impact or guidance change disclosed; product approval timeline uncertain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141546,"accession_number":"0001213900-25-064580","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2025-07-16T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"HeartBeam shareholders approve 3M share increase to equity plan, elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders voted to increase authorized shares under 2022 Equity Plan by 3M from 8.9M to 11.9M.","All nine director nominees elected with majority votes; broker non-votes of 11.6M on each nominee.","Ratification of CBIZ CPAs as auditor approved with 18.4M for, 55.9k against, 257.5k abstentions.","Equity plan amendment passed with 4.38M for, 2.72M against, 11.58M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.15,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159393,"accession_number":"0001213900-25-039490","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"HeartBeam CEO Robert Eno appointed to Board of Directors effective May 5, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Robert Eno joins Board effective May 5, 2025; Board expands from 8 to 9 members.","Eno has 30+ years medtech experience, previously CEO of Preview Medical, leadership at HeartFlow, OptiMedica.","Appointment supports commercialization of HeartBeam's 3D ECG technology; FDA clearance for 3D ECG received Dec 2024.","12-lead ECG Synthesis Software FDA application submitted Jan 2025; Early Access Program underway for clinical feedback.","Executive Chairman cites Eno's go-to-market expertise as key to strategic oversight and growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159392,"accession_number":"0001213900-25-035509","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2025-04-25T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"HeartBeam auditor resigns; CBIZ CPAs engaged; going concern noted","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum LLP resigned as auditor on April 21, 2025, due to CBIZ CPAs acquiring its attest business.","Audit committee engaged CBIZ CPAs as new independent auditor for fiscal year ending Dec 31, 2025.","2024 audit report included a going-concern explanatory paragraph; no adverse opinions on prior periods.","Material weaknesses in internal controls were reported and disclosed as remediated in 2024 10-K.","No disagreements or reportable events occurred during the past two fiscal years or interim period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177788,"accession_number":"0001213900-25-017245","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"HeartBeam raises additional ~$1.5M from over-allotment exercise in public offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwriter exercised over-allotment for 864,033 shares at $1.70, gross proceeds ~$1.5M.","Total offering increased to 6,746,386 shares and ~$11.5M gross proceeds.","Proceeds for commercial-readiness activities, R&D, regulatory projects, and working capital.","MDB Capital acted as underwriter; Paulson Investment participated as selected dealer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177787,"accession_number":"0001213900-25-014528","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"HeartBeam prices $10M public offering of 5.88M shares at $1.70 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 5,882,353 shares of common stock at $1.70/share; gross proceeds ~$10M.","Underwriter granted 588,235 warrants at $2.125/share, exercisable from Feb 2026 to Feb 2030.","Directors and officers subject to 180-day lock-up; company restricted from issuing equity for 180 days.","Net proceeds to fund commercial-readiness, R&D, regulatory projects, working capital.","FDA cleared HeartBeam system for arrhythmia; 510(k) submitted for 12-lead ECG synthesis software."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194493,"accession_number":"0001628280-24-043338","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2024-10-23T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"HeartBeam appoints Robert Eno as CEO; founder Vajdic moves to President","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert Eno named CEO effective Oct 21, 2024; base salary of $400,000 with 60% incentive bonus.","Founder Branislav Vajdic transitions to President, focusing on vector-based technology and AI.","Eno brings 30+ years of MedTech go-to-market experience; previously SVP Marketing at HeartFlow.","Company continues to pursue FDA 510(k) clearance for its credit card-sized ECG device.","No changes to Vajdic's compensation; transition described as long-planned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210823,"accession_number":"0001628280-24-039968","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2024-09-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"HeartBeam appoints Timothy Cruickshank as CFO; base salary $385K plus equity","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Timothy Cruickshank appointed CFO effective September 9, 2024.","Annual base salary of $385,000; eligible for 45% incentive bonus and 400,000-share option grant.","Cruickshank was CFO of ImpediMed from Oct 2019 to Mar 2024 with 15+ years medtech experience.","Succeeds Richard Brounstein, who retired in February and remained in advisory capacity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229229,"accession_number":"0001213900-24-053485","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"HeartBeam shareholders approve 3M share increase to equity plan and elect eight directors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders approved amendment to 2022 Equity Plan, increasing authorized shares from 5.9M to 8.9M (3M increase).","Eight directors elected (Ferrari, Vajdic, de Urioste, Ortigas-Wedekind, Elfrink, Strome, Nelson, Jaff).","Ratified Marcum LLP as independent auditor for fiscal year ending December 31, 2024.","Quorum of 15,510,613 votes (58.91% of outstanding shares) at June 12, 2024 annual meeting.","Broker non-votes of ~6.9M were recorded on director election and equity plan amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229228,"accession_number":"0001779372-24-000005","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"HeartBeam enters $17M at-the-market equity facility with Public Ventures, terminates prior AGP deal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New ATM sales agreement with Public Ventures allows sale of up to $17M of common stock at 3% commission.","Prior ATM agreement with A.G.P./Alliance Global Partners was terminated on May 1, 2024.","Net proceeds will be used for working capital and general corporate purposes.","Sales will occur from time to time at the Company's discretion; no assurance of any sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247817,"accession_number":"0001779372-24-000001","cik":1779372,"company_name":"HeartBeam, Inc.","ticker":"BEAT","form_type":"8-K","filed_at":"2024-02-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"HeartBeam CFO Richard Brounstein retires effective Feb 1, 2024; no successor named","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Richard Brounstein retired as CFO effective February 1, 2024; he served since 2015.","Brounstein will provide CFO advisory consulting services to assist transition.","No replacement CFO has been announced; CEO Branislav Vajdic signed the filing.","Retirement not due to disagreement with company or board (as stated)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":48574032.93651327,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}